Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Wala, Jeremiah A.; Hanna, Glenn J.

doi:10.1016/j.hoc.2023.05.009

Cited by 2 publications

(1 citation statement)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor antigen heterogeneity is a common problem in CAR-T cell therapy. Analyzing the expression levels of tumor antigens in tumor tissues showed that there are significant differences between patients with different tumors, which implies that the heterogeneity of a variety of tumor antigens must be taken into account in patient selection and assessment of the therapeutic efficacy of CAR-T cell therapy ( 13 – 15 ). Currently, the most frequently used strategy uses a combination of bispecific antibodies (BsAbs).…”

Section: Challenges Associated With the Use Of Car-t Cells In Solid T...mentioning

confidence: 99%

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Luo,

Zhang

2024

Front. Oncol.

View full text Add to dashboard Cite

Recent years have seen a marked increase in research on chimeric antigen receptor T (CAR-T) cells, with specific relevance to the treatment of hematological malignancies. Here, the structural principles, iterative processes, and target selection of CAR-T cells for therapeutic applications are described in detail, as well as the challenges faced in the treatment of solid tumors and hematological malignancies. These challenges include insufficient infiltration of cells, off-target effects, cytokine release syndrome, and tumor lysis syndrome. In addition, directions in the iterative development of CAR-T cell therapy are discussed, including modifications of CAR-T cell structures, improvements in specificity using multi-targets and novel targets, the use of Boolean logic gates to minimize off-target effects and control toxicity, and the adoption of additional protection mechanisms to improve the durability of CAR-T cell treatment. This review provides ideas and strategies for the development of CAR-T cell therapy through an in-depth exploration of the underlying mechanisms of action of CAR-T cells and their potential for innovative modification.

show abstract

Section: Challenges Associated With the Use Of Car-t Cells In Solid T...mentioning

confidence: 99%

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Luo,

Zhang

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Epigenetics Meets CAR-T-Cell Therapy to Fight Cancer

Santourlidis,

Araúzo-Bravo,

Erichsen

et al. 2024

Cancers

View full text Add to dashboard Cite

Based on the impressive success of Car-T-cell therapy in the treatment of hematological malignancies, a broad application for solid tumors also appears promising. However, some important hurdles need to be overcome. One of these is certainly the identification of specific target antigens on cancer cells. Hypomethylation is a characteristic epigenetic aberration in many tumor entities. Genome-wide screenings for consistent DNA hypomethylations in tumors enable the identification of aberrantly upregulated transcripts, which might result in cell surface proteins. Thus, this approach provides a new perspective for the discovery of potential new Car-T-cell target antigens for almost every tumor entity. First, we focus on this approach as a possible treatment for prostate cancer.

show abstract

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Cited by 2 publications

References 134 publications

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Epigenetics Meets CAR-T-Cell Therapy to Fight Cancer

Contact Info

Product

Resources

About